AccuraGen

About

AccuraGen Holdings, founded in 2013 and based in California, is a biotechnology company focused on developing liquid biopsy technology for cancer diagnostics and personalized treatment. The company’s core platform, Firefly, utilizes next-generation sequencing to detect low-frequency mutations in cell-free DNA, offering a non-invasive and highly sensitive method for molecular health monitoring. AccuraGen specializes in DNA and RNA sequencing for mutation detection in blood samples, supporting cancer treatment plans and molecular profiling. Their proprietary method employs rolling-circle amplification to enhance accuracy and efficiency in genetic analysis. The company has raised approximately $47.15 million in funding and operates with a small team, generating revenue under $5 million. AccuraGen collaborates with Complete Genomics to improve sequencing performance for minimal residual disease assays, contributing to advancements in oncology and healthcare.